Vol 60, No Supplement 3 | The Journal of Clinical Psychiatry

Article

Outcome in Schizophrenia: Beyond Symptom Reduction

J Clin Psychiatry 1999;60(suppl 3):3-7

Herbert Y. Meltzer, MD

Article

Methods of Cost-Effectiveness Analysis in the Evaluation of New Antipsychotics: Implications for Schizophrenia Treatment

J Clin Psychiatry 1999;60(suppl 3):9-14

Peter J. Neumann, ScD

Article

Mental Health Care From the Public Perspective: The Texas Medication Algorithm Project

J Clin Psychiatry 1999;60(suppl 3):16-20

A. John Rush, MD; Trisha Suppes, MD, PhD; Alexander L. Miller, MD; Marcia G. Toprac, PhD; M. Lynn Crismon, PharmD; Steven P. Shon, MD; Madhukar Trivedi, MD

Article

Cost-Utility Analysis in Schizophrenia

J Clin Psychiatry 1999;60(suppl 3):22-26

A. George Awad, MD, PhD; Lakshmi P. Voruganti, MD, MSc

Article

The Wisconsin Quality of Life Index: A Multidimensional Model for Measuring Quality of Life

J Clin Psychiatry 1999;60(suppl 3):29-31

Ronald Diamond, MD; Marion Becker, PhD

Article

Perspective and the Measurement of Costs and Benefits for Cost-Effectiveness Analysis in Schizophrenia

J Clin Psychiatry 1999;60(suppl 3):32-35

David Meltzer, MD, PhD

Article

What About the Patient?

J Clin Psychiatry 1999;60(suppl 3):38-41

Daniel E. Weisburd

Article

The Risperidone Outcomes Study of Effectiveness (ROSE): A Model for Evaluating Treatment Strategies in Typical Psychiatric Practice

J Clin Psychiatry 1999;60(suppl 3):42-47

Ramy Mahmoud, MD; Luella Engelhart, MA; Dan Ollendorf, MPH; Gerry Oster, PhD

Article

Cost of Treating Mental Illness From a Managed Care Perspective

J Clin Psychiatry 1999;60(suppl 3):49-52

John P. Docherty, MD

Article

Panel on Cost-Effectiveness in Health and Medicine Recommendations: Identifying Costs

J Clin Psychiatry 1999;60(suppl 3):54-56

Willard G. Manning, Jr., PhD

Article

Concluding Discussion: Pharmacoeconomic Factors Related to the Treatment of Schizophrenia

J Clin Psychiatry 1999;60(suppl 3):59-60

Volume 60 • 1999 • Supplement 3

Article

Outcome in Schizophrenia: Beyond Symptom Reduction

Methods of Cost-Effectiveness Analysis in the Evaluation of New Antipsychotics: Implications for Schizophrenia Treatment

Mental Health Care From the Public Perspective: The Texas Medication Algorithm Project

Cost-Utility Analysis in Schizophrenia

The Wisconsin Quality of Life Index: A Multidimensional Model for Measuring Quality of Life

Perspective and the Measurement of Costs and Benefits for Cost-Effectiveness Analysis in Schizophrenia

What About the Patient?

The Risperidone Outcomes Study of Effectiveness (ROSE): A Model for Evaluating Treatment Strategies in Typical Psychiatric Practice

Cost of Treating Mental Illness From a Managed Care Perspective

Panel on Cost-Effectiveness in Health and Medicine Recommendations: Identifying Costs

Concluding Discussion: Pharmacoeconomic Factors Related to the Treatment of Schizophrenia

ELSEWHERE:

FOLLOW US:

Volume 60 • 1999 • Supplement 3

Article

Outcome in Schizophrenia: Beyond Symptom Reduction

Methods of Cost-Effectiveness Analysis in the Evaluation of New Antipsychotics: Implications for Schizophrenia Treatment

Mental Health Care From the Public Perspective: The Texas Medication Algorithm Project

Cost-Utility Analysis in Schizophrenia

The Wisconsin Quality of Life Index: A Multidimensional Model for Measuring Quality of Life

Perspective and the Measurement of Costs and Benefits for Cost-Effectiveness Analysis in Schizophrenia

What About the Patient?

The Risperidone Outcomes Study of Effectiveness (ROSE): A Model for Evaluating Treatment Strategies in Typical Psychiatric Practice

Cost of Treating Mental Illness From a Managed Care Perspective

Panel on Cost-Effectiveness in Health and Medicine Recommendations: Identifying Costs

Concluding Discussion: Pharmacoeconomic Factors Related to the Treatment of Schizophrenia

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Subscribe to readmore articles

Subscribe to read
more articles